Factors associated with potential drug–drug interactions detected by Lexicomp drug checker
| Variable | B | P value | 95% Cl |
| Lexicomp total interactions | |||
| White blood cells | −0.151 | 0.006 | −0.260 to −0.043 |
| C-reactive protein | 0.020 | 0.046 | 0.000 to 0.039 |
| Glucose | 0.325 | 0.003 | 0.109 to 0.540 |
| Тriglycerides | −0.272 | 0.034 | −0.524 to −0.021 |
| Number of prescribed drugs | 1.860 | 0.000 | 1.662 to 2.059 |
| Antipsychotics | −1.627 | 0.036 | −3.145 to −0.108 |
| Hypnotics and sedatives | −0.649 | 0.012 | −1.153 to −0.145 |
| Antidepressants | −1.275 | 0.000 | −1.879 to −0.670 |
| Antiepileptics | −0.636 | 0.047 | −1.265 to −0.008 |
| Dopaminergic drugs | −2.681 | 0.001 | −4.283 to −1.078 |
| Antiarrhythmic drugs | −0.865 | 0.031 | −1.653 to −0.078 |
| Anticoagulants | 1.729 | 0.000 | 0.839 to 2.620 |
| Antibiotic drugs | 1.262 | 0.000 | 0.617 to 1.907 |
| Antacids | 2.558 | 0.000 | 1.735 to 3.381 |
| Antihistamines | −1.120 | 0.032 | −2.141–−0.100 |
| Nonsteroidal anti-inflammatory drugs (NSAIDS) | 1.165 | 0.000 | 0.534 to 1.796 |
| Tetanus vaccine | 1.566 | 0.006 | 0.448 to 2.684 |
| Vitamins | 1.910 | 0.000 | 1.278 to 2.542 |
| Number of diagnoses | −1.306 | 0.000 | −1.695 to −0.918 |
| Dyslipidaemia | 1.332 | 0.001 | 0.533 to 2.130 |
| Urinary tract infection | −0.861 | 0.029 | −1.631 to −0.090 |
| Hypertension | −1.301 | 0.000 | −1.970 to −0.631 |
| Number of associated comorbidities | 0.838 | 0.000 | 0.410 to 1.266 |
| Allergy | −1.276 | 0.001 | −1.992 to −0.560 |
| Number of interactions in which the route of the drug increased the manifestation of the interaction | 0.878 | 0.000 | 0.584 to 1.172 |
| Number of interactions in which the form of the drug increased the manifestation of the interaction | 0.724 | 0.000 | 0.447 to 1.001 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.767; F (p)=51.91 (0.000)* | 1.328 | 0.000 | 0.761 to 1.894 |
| X-avoid combination | |||
| White blood cell count | 0.033 | 0.019 | 0.005 to 0.060 |
| Glucose | 0.062 | 0.044 | 0.123 to −0.002 |
| Antipsychotic drugs | −0.229 | 0.040 | −0.447 to −0.010 |
| Anticholinergic drugs | 0.204 | 0.010 | 0.048 to −0.360 |
| Anticoagulant drugs | 0.356 | 0.003 | 0.118 to 0.593 |
| Antibiotic drugs | 0.276 | 0.004 | 0.091 to 0.462 |
| Antacid drugs | −0.244 | 0.001 | −0.435 to −0.052 |
| Antidiabetic drugs | 0.258 | 0.037 | 0.016 to 0.501 |
| Antihistamines | 0.500 | 0.001 | 0.215 to 0.785 |
| Bronchodilators | −0.640 | 0.003 | −1.056 to −0.223 |
| Respiratory infection | −0.351 | 0.001 | −0.557 to −0.144 |
| Number of associated comorbidities | 0.159 | 0.033 | 0.013 to 0.305 |
| Chronic obstructive pulmonary disease (COPD) | −0.554 | 0.028 | −1.047 to −0.061 |
| Renal failure | 0.309 | 0.047 | 0.004 to 0.613 |
| Allergy | −0.253 | 0.010 | −0.443 to −0.062 |
| Number of interactions in which the route of the drug increased the manifestation of the interaction | 0.594 | 0.000 | 0.520 to 0.668 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.489; F (p)=22.1 (0.000)* | 0.145 | 0.048 | 0.001 to 0.290 |
| D-consider therapy modification | |||
| Total bilirubin | −0.017 | 0.047 | −0.034 to −0.000 |
| Number of pharmacological/therapeutic subgroups (second level of ATC classification) | 0.180 | 0.000 | 0.103 to 0.257 |
| Hypnotics and sedatives | −0.243 | 0.023 | −0.452to −0.033 |
| Dopaminergic drugs | −0.976 | 0.005 | −1.657 to −0.295 |
| Statins | 0.955 | 0.006 | 0.282 to 1.628 |
| Antacids | 0.616 | 0.000 | 0.285 to 0.958 |
| Diagnosis number | −0.246 | 0.000 | −0.382 to −0.111 |
| Dyslipidaemia | −1.093 | 0.000 | −1.705 to −0.481 |
| Cerebrovascular accident | 0.685 | 0.025 | 0.088 to 1.282 |
| Tumour | −0.921 | 0.002 | −1.490 to −0.352 |
| Alcoholic | −0.286 | 0.031 | −0.547 to −0.026 |
| Number of interactions in which the route of the drug increased the manifestation of the interaction | −0.225 | 0.001 | −0.352 to −0.099 |
| Number of interactions in which the form of the drug increased the manifestation of the interaction | 0.683 | 0.000 | 0.563 to 0.802 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.383; F (p)=17.669 (0.000)* | 0.320 | 0.008 | 0.084 to 0.1556 |
*Statistically significant.
ATC, Anatomical Therapeutic Chemical; B, unstandardised coefficient; p, statistical significance.